[go: up one dir, main page]

NO952650L - Nye peptider - Google Patents

Nye peptider

Info

Publication number
NO952650L
NO952650L NO952650A NO952650A NO952650L NO 952650 L NO952650 L NO 952650L NO 952650 A NO952650 A NO 952650A NO 952650 A NO952650 A NO 952650A NO 952650 L NO952650 L NO 952650L
Authority
NO
Norway
Prior art keywords
compounds
phe
cooh
amino acid
formula
Prior art date
Application number
NO952650A
Other languages
English (en)
Other versions
NO952650D0 (no
Inventor
Peter Schiller
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Publication of NO952650D0 publication Critical patent/NO952650D0/no
Publication of NO952650L publication Critical patent/NO952650L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/70Enkephalins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06078Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0812Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1002Tetrapeptides with the first amino acid being neutral
    • C07K5/1016Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Forbindelser av formel (1) samt fremgangsmåter for deres fremstilling, deres farmasøytiske preparater og deres anvendelse. Forbindelsene av formel (I) er nyttige i terapi, spesielt som analgetika og som immunsuppressive midler. R3, R4, RS, Rg er alle H eller R4 og RS er begge H og R3 og Rg er begge lavere alkylgrupper eller R3, R$. Rg er alle H og R4 er F. Cl. Br. OH, NH2 eller N02; R? er C = O eller CH2; Rg er H eller en lavere alkylgruppe: RQ er (II), hvor m er 0-2 eller (HI) eller (IV) eller (V) eller (VI) eller (VII) eller (VHI) hvor RIO er H. F. Cl, Br eller I og m er 0-2: RI \ er OH, NH2 eller (IX), hvor R12 er H, NO2- F. Cl, Br eller I. m er 0-2. Rj3 er COOH. CONHo. CH2OH, eller en hvilken som helst ytterligere aminosyre eller peptidsegmem. eller RU er (X) hvor Ri4 er COOH. CONH2> CC^OH, eller en hvilken som helst ytter- ligere aminosyre eller peptidsegmem: med unntakelse av de forbindelser hvor R!, R2, RS, R4- RS- Re og Rg alle er H, R-; er C = O og Rg er (XI) og RU er Phe-OH, Phe-NH2, OH eller NH2.
NO952650A 1993-01-05 1995-07-04 Nye peptider NO952650L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9300012A SE9300012D0 (sv) 1993-01-05 1993-01-05 New peptides
PCT/SE1993/001090 WO1994015959A1 (en) 1993-01-05 1993-12-20 New peptides

Publications (2)

Publication Number Publication Date
NO952650D0 NO952650D0 (no) 1995-07-04
NO952650L true NO952650L (no) 1995-08-30

Family

ID=20388466

Family Applications (1)

Application Number Title Priority Date Filing Date
NO952650A NO952650L (no) 1993-01-05 1995-07-04 Nye peptider

Country Status (25)

Country Link
US (1) US5602099A (no)
EP (1) EP0678099A1 (no)
JP (1) JPH08505386A (no)
KR (1) KR960700269A (no)
CN (1) CN1096515A (no)
AP (1) AP508A (no)
AU (1) AU681372B2 (no)
CA (1) CA2152380A1 (no)
CZ (1) CZ171195A3 (no)
EE (1) EE9400326A (no)
FI (1) FI953302A0 (no)
HU (1) HUT72597A (no)
IL (1) IL108169A0 (no)
IS (1) IS4115A (no)
LV (1) LV10962B (no)
MX (1) MX9400255A (no)
NO (1) NO952650L (no)
NZ (1) NZ259597A (no)
PL (1) PL309778A1 (no)
SE (1) SE9300012D0 (no)
SI (1) SI9400005A (no)
SK (1) SK83995A3 (no)
WO (1) WO1994015959A1 (no)
YU (1) YU394A (no)
ZA (1) ZA9455B (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU683121B2 (en) * 1993-12-23 1997-10-30 Novo Nordisk A/S Compounds with growth hormone releasing properties
IS4261A (is) * 1994-02-21 1995-08-22 Astra Aktiebolag Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra
SE9503924D0 (sv) * 1995-08-18 1995-11-07 Astra Ab Novel opioid peptides
IL114046A0 (en) * 1994-06-20 1995-10-31 Astra Ab New opioid peptide antagonists
RU2067000C1 (ru) * 1994-06-29 1996-09-27 Владислав Исакович Дейгин Пептид и способ его получения
US6184208B1 (en) 1994-06-29 2001-02-06 Immunotech Developments Inc. Peptide, a method for its preparation and a pharmaceutical composition containing the peptide
SE9402880D0 (sv) * 1994-08-30 1994-08-30 Astra Ab New peptide derivatives
US5780589A (en) * 1994-11-30 1998-07-14 The United States Of America As Represented By The Department Of Health And Human Services Ultraselective opioidmimetic peptides and pharmacological and therapeutic uses thereof
AU708620B2 (en) * 1995-03-29 1999-08-05 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP0837857A4 (en) * 1995-03-29 1998-08-05 Merck & Co Inc Inhibitors of farnesyl-protein transferase
DE19512484A1 (de) 1995-04-04 1996-10-17 Bayer Ag Kohlenhydratmodifizierte Cytostatika
SE9600769D0 (sv) * 1996-02-28 1996-02-28 Astra Ab Compounds useful as analgesic
US6903075B1 (en) 1997-05-29 2005-06-07 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
EP1001764A4 (en) * 1997-05-29 2005-08-24 Merck & Co Inc HETEROCYCLIC AMIDE COMPOUNDS AS INHIBITORS OF CELL ADHESION
US6703381B1 (en) 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
US6306576B1 (en) * 1999-02-19 2001-10-23 Cleveland Clinic Foundation Diagnostic methods for asthma
US7601739B2 (en) 2003-08-08 2009-10-13 Virgina Commonwealth University Compounds having antiestrogenic and tissue selective estrogenic properties, and compounds with anti-androgenic properties for treatment of prostate cancer and androgen receptor dependent diseases
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
AU2005286733B2 (en) * 2004-09-23 2009-11-05 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
EP3160497A4 (en) * 2014-06-27 2018-01-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Conjugates for immunotherapy

Also Published As

Publication number Publication date
US5602099A (en) 1997-02-11
JPH08505386A (ja) 1996-06-11
NZ259597A (en) 1996-07-26
WO1994015959A1 (en) 1994-07-21
CZ171195A3 (en) 1996-09-11
IL108169A0 (en) 1994-04-12
FI953302L (fi) 1995-07-04
LV10962A (lv) 1995-12-20
HU9502041D0 (en) 1995-09-28
AU5844894A (en) 1994-08-15
PL309778A1 (en) 1995-11-13
HUT72597A (en) 1996-05-28
SI9400005A (en) 1994-12-31
NO952650D0 (no) 1995-07-04
FI953302A7 (fi) 1995-07-04
AU681372B2 (en) 1997-08-28
KR960700269A (ko) 1996-01-19
YU394A (sh) 1997-07-31
FI953302A0 (fi) 1995-07-04
EE9400326A (et) 1996-04-15
AP9400605A0 (en) 1994-01-31
MX9400255A (es) 1994-07-29
EP0678099A1 (en) 1995-10-25
SE9300012D0 (sv) 1993-01-05
CN1096515A (zh) 1994-12-21
AP508A (en) 1996-07-22
SK83995A3 (en) 1996-09-04
IS4115A (is) 1994-07-06
CA2152380A1 (en) 1994-07-21
ZA9455B (en) 1994-07-05
LV10962B (en) 1997-04-20

Similar Documents

Publication Publication Date Title
NO952650L (no) Nye peptider
NO941611D0 (no) Nye aminosyrederivater, fremgangsmåte for deres fremstilling og farmasöytiske preparater inneholdende disse forbindelser
LTIP1947A (en) Novel peptides derivatives, process for their preparation, pharmaceutical compositions and use starting materials in synthesis of a serine protease inhibitors
EP0849256A4 (en) AMIDE COMPOUNDS AND THEIR USE
MX9801716A (es) Derivados de meta-guanidina, urea, tiourea o acido aminobenzoico azaciclico, como antagonistas de integrina.
NO894919L (no) Nye aminobenzoater.
ATE159945T1 (de) Beta-aminoalkyl und beta-n- peptidylaminoalkylborsäure
HUP9902410A2 (hu) Amidinszármazékok, előállításuk, trombininhibitorként való alkalmazásuk, a vegyületeket tartalmazó gyógyászati készítmények
CA2078790A1 (en) 3-benzylidene-1-carbamoyl-2-pyrrolidone analogues
NO308005B1 (no) Ureidoderivater av naftalenfosfonsyrer, farmasøytisk preparat inneholdende slike derivater, anvendelse av derivatene samt mellomprodukt
BRPI0008753B8 (pt) composto de amida, processo para preparar um composto de amida, composição farmacêutica e uso de um composto de amida
FR2712591B1 (fr) Nouvelles arylpipérazines dérivées d'indole, leur préparation et leur utilisation thérapeutique.
EE03180B1 (et) Bombesiini antagonistpeptiidid, farmatseutiline kompositsioon ja kasutamine
ES8900045A1 (es) Procedimiento para preparar derivados de 2-amino-tiazol
GB1535967A (en) Antilipidemic para-(aryl(alkyl or alkenyl)-amino)-benzoic acid derivatives
HUP0001396A2 (hu) 3-Amino-3 aril-propán-1-ol-származékok, előállításuk és felhasználásuk
ZA935340B (en) Phosphonated arylethanolamine compounds with anti-hyperglycemic and/or anti-obesity activity
DK149091C (da) Analogifremgangsmaade til fremstilling af peptider indeholdende 2-7 aminosyrerester, desaminodipeptider eller amider deraf med ubiquitin-lignende aktivitet eller farmaceutisk acceptable syreadditionssalte deraf
HUP9800970A2 (hu) Eljárás neurogén és nem neurogén gyulladásgátló, valamint fájdalomcsillapító hatású heptapeptid szomatosztatinszármazékokat és peptidomimetikumokat tartalmazó gyógyászati készítmények előállítására
Tamai et al. Relationship between structure and papain inhibitory activity of epoxysuccinyl amino acid derivatives
AU623649B2 (en) New sulphurcontaining eicosanoides and their application in pharmacy and in cosmetics
EP0222283A3 (en) Amino-acid derivatives
CA2127067A1 (fr) Derives d'acide phosphonique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ATE101126T1 (de) Amide von cyclomethylen-1,2 bicarbonsaeure mit therapeutischer wirkung, verfahren zu deren herstellung sowie diese enthaltende pharmazeutische zusammensetzungen.
DE68923572D1 (de) Peptide.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application